Global Albuterol Sulfate Inhalation Aerosol Market Size, Share and Trends Analysis Report, By Type (Albuterol Sulfate Inhalation Aerosol 90 mcg, Albuterol Sulfate Inhalation Aerosol 108 mcg, and Albuterol Sulfate Inhalation Aerosol 120 mcg), By Application (Children and Adults), Forecast (2022-2028)

The global albuterol sulfate inhalation aerosol market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The global market is growing due to the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease. According to World Health Organization in May 2021, Asthma has affected 262 million people in 2019 and caused 461,000 deaths globally. Asthma almost affects almost 5%-10% of the global population that accounts for 23.4 million people including 7 million children. The demand for albuterol sulfate inhalation aerosol has increased substantially during the COVID-19 pandemic as doctors were prescribing this drug for the treatment of COVID-19 patients having breathing and respiratory problems. Additionally, the presence of key manufacturing companies and huge investment in research and development activities is boosting the growth of the global albuterol sulfate inhalation aerosol market in the forecast period.

For instance, In June 2021, the US Food and Drug Administration (USFDA) has announced the approval of albuterol sulfate inhalation aerosol 90mcg for the treatment and prevention of bronchospasm and asthma above 4 years of age. In February 2020, USFDA approves the first generic version of albuterol sulfate inhalation aerosol named ProAir HFA for the treatment of asthma and other pulmonary diseases. In April 2020, USFDA approved the generic version of the most commonly used albuterol sulfate inhalation aerosol named Proventil HFA albuterol sulfate metered-dose inhaler 90 mcg for the treatment of reversible obstructive airway disease. In April 2020, Cipla announced its approval of its abbreviated new drug application for albuterol sulfate inhalation aerosol 90mcg from USFDA. It will be used to treat acute episodes of bronchospasm or prevention of asthmatic symptoms. In September 2021, AstraZeneca published an article stating that the fixed-dose of albuterol 180 mcg and budesonide 160 mcg has shown significant benefits in patients with asthma. The combination of albuterol 180 mcg and budesonide 160 mcg is known as MANDALA PT027 that was developed by AstraZeneca and Avillion LLP. The phase III trial of this drug has met the primary endpoint in treating patients with asthma and other pulmonary disorder.

Some major players in the market include Merck & Co., Inc., GlaxoSmithKline plc. , Teva Pharmaceutical Industries Ltd., Zydus Group among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2020, Perrigo Co. plc has partnered with Catalent Pharma Solutions for the USFDA approval of Perrigo Co. plc abbreviated new drug application for generic albuterol sulfate inhalation aerosol. Perrigo Co. plc is launching a limited quantity of albuterol sulfate inhalation aerosol and the collaboration with Catalent Pharma Solutions will meet the future demand of this drug globally.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Merck & Co., Inc., GlaxoSmithKline plc. , Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Albuterol Sulfate Inhalation Aerosol Market Report by Segment

By Type

• Albuterol Sulfate Inhalation Aerosol90 mcg
• Albuterol Sulfate Inhalation Aerosol108 mcg
• Albuterol Sulfate Inhalation Aerosol120 mcg

By Application

• Children
• Adults

Global Albuterol Sulfate Inhalation Aerosol Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa